| Literature DB >> 25923888 |
Lismeia Raimundo Soares1, Daniela Cardeal da Silva1, Claudio R Gonsalez1, Felipe G Batista1, Luiz Augusto M Fonseca2, Alberto J S Duarte1, Jorge Casseb1.
Abstract
INTRODUCTION: Highly Active Antiretroviral Therapy (HAART) has improved and extended the lives of thousands of people living with HIV/AIDS around the world. However, this treatment can lead to the development of adverse reactions such as lipoatrophy/lipohypertrophy syndrome (LLS) and its associated risks.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25923888 PMCID: PMC4435007 DOI: 10.1590/S0036-46652015000200002
Source DB: PubMed Journal: Rev Inst Med Trop Sao Paulo ISSN: 0036-4665 Impact factor: 1.846
Socio-demographic characteristics of the 227 HIV-1-infected individuals by gender
| Variable | Males (152) | Females (75) |
|
|---|---|---|---|
|
| 43 ± 8 | 42 ± 9 | NS |
|
| NS | ||
| Unknown | 13 (8.55) | 5 (6.66) | |
| None | 1 (0.65) | 1 (1.33) | |
| ≤ 8 years | 41 (26.97) | 22 (29.33) | |
| 9-11 years | 62 (40.78) | 39 (52) | |
| >11 years | 38 (25) | 7 (9.33) | |
|
| NS | ||
| Unknown | 12 (7.89) | 5 (6.66) | |
| No | 34 (22.36) | 4 (5.33) | |
| With 2 persons | 31 (20.39) | 13 (17.33) | |
| With more than 2 persons | 74 (48.68) | 52 (69.33) | |
|
| NS | ||
| No answer | 15 (9.86) | 6 (8) | |
| Single | 83 (54.60) | 20 (26.66) | |
| Married | 24 (15.78) | 20 (26.66) | |
| Divorced | 9 (5.92) | 17 (22.66) | |
|
| NS | ||
| No answer | 15 (9.86) | 8 (10.66) | |
| Owner | 82 (53.94) | 42 (56) | |
| Tenant | 44 (28.94) | 20 (26.66) | |
| Other | 11 (7.23) | 4 (5.33) | |
|
| NS | ||
| No answer | 10 (6.57) | 6 (8) | |
| Employed | 103 (67.76) | 42 (56) | |
| Unemployed | 39 (25.65) | 27 (36) | |
|
| NS | ||
| None | 10 (6.57) | 12 (16) | |
| < 1 | 11 (7.23) | 13 (17.33) | |
| 1-5 | 97 (63.81) | 36 (48) | |
| 6-10 | 16 (10.52) | 6 (8) | |
| > 10 | 4 (2.63) | - | |
| No answer | 13 (8.55) | 7 (9.33) | |
|
| 59 (38.81%) | 33 (44%) |
NS: Not statistically significant when p value > 0.05; Income: 1 minimum wage = ~ U$300.00.
Cardiovascular risk according to sex, anthropometric variables and self-reported groups of lipoatrophy/lipohypertrophy syndrome (LLS)
| Variables | Males | Females | ||||||
|---|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 |
| Group 1 | Group 2 | Group 3 |
| |
|
| 59 | 52 | 41 | 33 | 18 | 24 | ||
|
| 7 ± 4 | 5 ± 4 | - | 0.02 | 7 ± 4 | 4 ± 5 | 0.01 | |
|
| 542 (335-732) | 359 (187-503) | 431 (287-628) | 0.01 | 427 (310-607) | 342 (267-468) | 474 (396-804) | 0.04 |
|
| ||||||||
|
| 9 ± 5 | 5 ± 4 | 2 ± 3 | 0.001 | 9 ± 5 | 5 ± 5 | 5 ± 6 | 0.003 |
|
| 400 (400-1053) | 400 (400-3309) | 15000 (1993-65675) | 0.000 | 436 (400-6178) | 400 (138-1576) | 4410 (1632-14350) | 0.009 |
|
| 0.001 | 0.007 | ||||||
| Depletion | 50 (84.74%) | 42 (80.76%) | 20 (48.78%) | 26 (78.78%) | 15 (83.33%) | 12 (50%) | ||
| Eutrophic | 4 (6.77%) | 6 (11.53%) | 3 (7.31%) | 6 (18.18%) | 3 (16.66%) | 4 (16.66%) | ||
| Excess | 5 (8.47%) | 4 (7.69%) | 17 (41.46%) | 1 (3.03%) | - | 8 (33.33%) | ||
|
| 32 ± 7 | 35 ± 9 | 38 ± 7 | 0.001 | 39 ± 9 | 45 ± 8 | 46 ± 7 | 0.003 |
|
| ||||||||
|
| 0.72 | 0.05 | ||||||
| Depletion | - | - | ||||||
| Eutrophic | 32 (54.23%) | 28 (53.84%) | 20 (48.78%) | - | 1 (5.55%) | - | ||
| Excess | 27 (45.76%) | 24 (46.15%) | 20 (48.78%) | 12 (36.36%) | 13 (72.22%) | 12 (50%) | ||
|
| 0.03 | 0.014 | ||||||
| Depletion | - | 1 (2.43%) | - | - | ||||
| Eutrophic | 4 (6.77%) | 16 (30.76%) | 6 (11.53%) | - | 1 (4.16%) | |||
| Excess | 53 (89.83%) | 33 (63.46%) | 31 (75.60%) | 33 (100%) | 18 (100%) | 23 (95.83%) | ||
|
| 0.13 | 0.19 | ||||||
| Depletion | 4 (6.77%) | - | 3 (7.31%) | - | - | - | ||
| Eutrophic | 22 (37.28%) | 26 (50%) | 9 (21.95%) | 4 (12.12%) | 5 (27.77%) | 2(8.33%) | ||
| Excess | 33 (55.93%) | 25 (48.07%) | 27 (65.85%) | |||||
|
| 0.001 | 0.005 | ||||||
| Low and Intermediate | 27 (45.76%) | 32 (61.53%) | 28 (68.29%) | 2 (6.06%) | 4 (22.22%) | 5 (20.83%) | ||
| High and very high | 32 (54.23%) | 20 (38.46%) | 12 (29.26%) | 31 (93.93%) | 14 (77.77%) | 19 (79.16%) | ||
|
| 0.63 | 0.01 | ||||||
| Low and intermediate | 52 (88.13%) | 49 (94.23%) | 35 (85.36%) | 11 (33.33%) | 11 (61.11) | 13 (54.16%) | ||
| High | 5 (8.47%) | 3 (5.76%) | 5 (12.19%) | 22 (66.66%) | 7 (38.88%) | 5 (20.83%) | ||
|
| 0.63 | 0.01 | ||||||
| Men ≥ 90 and women ≥ 80 | 30 (50.84%) | 24 (46.15%) | 18 (43.90%) | 30 (90.90%) | 10 (55.55%) | 19 (79.16%) | ||
SD = Standard Deviation. Group 1 = Self-reported lipoatrophy/lipohypertrophy and HAART. Group 2 = HAART and no lipoatrophy/lipohypertrophy and Group 3 = Not on HAART.For relationships between categorical and quantitative variables with normal distribution the t student’s test was used (for two variables). The association between the study variables (anthropometry and body fat distribution) was performed according to defined groups (G1, G2 and G3) and analyzed by ANOVA (used for 3 variables), with a confidence level of 95% and significance of 5%, according to the comparison test of Tukey.